Cancer Chemother Pharmacol (1996) 38: 1— 8
( Springer-Verlag 1996
OR IG INA L A R TI C LE
Hideya Takeuchi · Hideo Baba · Yoshihiko Maehara
Keizo Sugimachi · Robert A Newman
Flavone acetic acid increases the cytotoxicity of mitomycin C
when combined with hyperthermia
Received: 1 February 1995/Accepted: 6 July 1995
Abstract Flavone acetic acid (FAA, NSC 347512) is
known to selectively reduce tumor blood flow. Taking
advantage of this pharmacodynamic effect, we have
previously shown that FAA in combination with hyperthermia (HT) can produce a marked improvement
in antitumor response in mice. In the present study, we
investigated whether FAA could increase the cytotoxicity of mitomycin C (MMC), a bioreductive drug with
selective cytotoxicity against hypoxic cells, under either
normothermic or hyperthermic conditions. In vitro, the
cytotoxicity of MMC against B16 melanoma cells was
not enhanced with exposure to FAA at concentrations
less than 100 lg/ml, even when combined with HT
(43°C, 60 min). The cytotoxicity of MMC (1 lg/ml) at
pH 6.5, however, was enhanced by exposure of cells to
hypoxia in combination with HT. In vivo, the tumor
growth time, calculated as the time required to double
the initial tumor volume, was 5.2, 6.8, 8.5, and 15.0 days
with FAA (150 mg/kg) alone, MMC (4 mg/kg) alone,
FAA#MMC, or FAA#MMC#HT (43°C, 15 min)
treatment groups, respectively. Antitumor response obtained in animals treated with FAA plus MMC with
HT was clearly better than that obtained in any of the
other groups. Scheduling of FAA, MMC, and HT was
found to be important in producing optimal antitumor
response. Administration of MMC (4 mg/kg) prior to
FAA (150 mg/kg) and subsequent HT treatment was
superior to administration of FAA before MMC. In an
attempt to explain these findings, the influence of FAA
H. Takeuchi ( ) · H. Baba · K. Sugimachi
Cancer Center of Kyushu University Hospital, 3-1-1 Maidashi,
Higashi-ku, Fukuoka 812, Japan
(Fax 81—92-632—3001)
Y. Maehara · K. Sugimachi
Department of Surgery II, Faculty of Medicine, Kyushu University,
3-1-1 Maidashi, Higashi-ku, Fukuoka 812, Japan
R.A. Newman
The University of Texas, M. D. Anderson Cancer Center, Houston,
Texas 77030, USA
on blood flow in skeletal muscle and in tumor was
examined using a laser blood flowmeter. FAA administration to mice produced a 75% reduction in blood
flow to the tumor for up to 2 h but had no detectable
effect on normal skeletal blood flow. Our current explanation of the increased antitumor response achieved
with the combination of MMC, FAA, and HT is as
follows. The FAA-mediated decrease in blood flow to
the tumor, when combined with HT, may produce
sufficiently hypoxic conditions to significantly increase
the antitumor efficacy of the bioreductive drug, MMC.
We believe that clinical testing of this combined drug
treatment with hyperthermia is warranted.
Key words Flavone acetic acid · Mitomycin C ·
Hyperthermia · Tumor blood flow · Hypoxia
Introduction
Flavone acetic acid (FAA) was initially prepared as
a potential anti-inflammatory agent by Lipha (France)
in 1984. Antitumor activity against several murine solid
tumors and human xenografts has been reported [10,
33, 38]. Synergistic cytotoxicity with the cytokine, interleukin 2 [44], has renewed interest in FAA and has
prompted new clinical trials [18]. Recently, one partial
response was reported in a patient with renal cell carcinoma [30]. Although the precise mechanism of the
broad spectrum of antitumor activity of FAA against
murine solid tumors is unknown, a number of unique
pharmacological effects of FAA on solid tumors has
been demonstrated. For example, it has been shown to:
(1) increase hypoxia within solid tumors by reducing
tumor blood flow, resulting in hemorrhagic necrosis
[45]; (2) decrease ATP concentration and inhibit
plasma membrane Na`/K`-ATPase activity by interfering with the generation of adenosine diphosphate
and with inorganic phosphate utilization [9]; (3) mediate alterations in natural killer cells, tumor necrosis
2
factor, and other components of the immune system [3,
10]; and (4) result in extensive single-strand DNA
breaks [2]. Among these mechanisms, reduction of
tumor blood flow has been thought to be most responsible for the cytotoxic action towards solid tumors [27].
Mitomycin C (MMC), a naturally occurring prototype bioreductive alkylating agent with a wide range of
antitumor activity against human tumors, has been
shown to be selectively cytotoxic toward hypoxic tumor cells in vitro [16, 21, 22, 41] and in vivo [35] by
producing DNA cross-links. Hyperthermia (HT) has
now been widely used in clinical situations [14, 40],
and would appear to have therapeutic potential in the
treatment of solid tumors, especially when used in
combination with other treatments such as radiation
[13] and chemotherapy including MMC [4] and FAA
[37]. The antitumor effect of HT is greatly enhanced by
hypoxia [34] or acidic conditions [12]. The development of thermotolerance within cultured cells has also
been shown to be inhibited by acidic pH [29].
In the present study, we investigated whether the
cytotoxicity and antitumor efficacy of MMC could be
enhanced in vitro and in vivo by the administration of
FAA in combination with HT. We proposed that FAA
would produce a marked reduction in tumor blood
flow at a time when MMC would reach its maximum
intra-tumor concentration. The bioreductive drug
would then be trapped and kept at a high concentration in the tumor, where it would be more effective due
to FAA-mediated hypoxia. Moreover, a FAA-induced
hypoxic condition would also enhance the cytotoxicity
of HT. Thus, the combination of FAA plus MMC with
HT might be uniquely synergistic against solid tumor
growth. Here, we describe the combined effect of FAA
plus MMC in combination with HT against B16
melanoma cells, and discuss potential mechanisms of
the enhanced cytotoxicity of the combined treatment.
Materials and methods
Drugs
FAA was obtained from Professor R.A. Newman (Department of
Clinical Investigation, M.D. Anderson Cancer Center, Houston,
Tex.). FAA was dissolved in physiological saline just prior to use.
MMC was obtained from Kyowa Hakko (Tokyo, Japan) and was
dissolved in Hank’s solution immediately prior to use.
B16 cell culture
For in vitro experiments, B16 melanoma cells (obtained from Dr. S.
Taniguchi, Medical Institute of Bioregulaiton of Kyushu University,
Fukuoka, Japan) were cultured in monolayers on 60-mm plastic
dishes (Corning 25010, Iwaki Glass, Japan) using Eagle’s minimal
essential medium (Nissui Pharmaceutical, Tokyo, Japan) supplemented with 10% fetal calf serum (Gibco Laboratories, Grand
Island, N.Y.). Cells were maintained at 37°C in a humidified 5%
CO atmosphere.
2
Colony formation assay
Three hundred exponentially growing B16 melanoma cells were
placed in 60-mm dishes without any drugs and were incubated at
37°C for 24 h. Cells were then exposed to various concentrations of
both MMC (0.1—5 lg/ml) and FAA (0.1—100 lg/ml) at 37°C for
60 min. The concentration of FAA examined in this study, below
100 lg/ml, is a clinically achievable level. In groups treated with HT,
cells were incubated at 43°C for 60 min simultaneously with drugs.
After treatment, cells were washed 3 times with phosphate-buffered
saline and incubated in fresh medium. After 1 week, colonies were
stained with Giemsa solution and those which contained more than
50 cells were counted. Effects of treatment were evaluated by determining the extent of inhibition of colony formation. Each experiment was done in triplicate.
Hypoxic conditions
Cells were exposed to hypoxic conditions induced by incubation for
4 h in a humidified mixure of 95% N and 5% CO , using a Bellco
2
2
glass incubator (Bellco Glass, USA) [20]. Cells were preincubated
for 3 h in a humidified atmosphere followed by exposure to the
drugs for 1 h.
Regulation of pH
The pH was regulated by using different concentrations of NaHCO
3
in the medium while maintaining the CO concentration constant at
2
5% [1]. Cells were exposed to a given pH for the same duration as
the hypoxic treatment, 3 h preincubation and 1 h incubation in the
presence of MMC (1 lg/ml). The maximum pH deviation during
hypoxic treatment was less than 0.05 throughout each experiment.
Exposure of B16 melanoma cells to either hypoxia or acidic pH (in
the range 6.5—7.4) or the combination of both conditions for 4 h had
no adverse effect on cell survival.
Animals
C57BL/6NCrj male mice (5 weeks old; 18—23 g) were obtained from
Charles River Japan (Tokyo, Japan), and were housed under constant temperature and humidity conditions. Mice were fed a diet of
standard laboratory chow, allowed free access to water, and housed
six per cage in a controlled environment with a 12-h light/dark cycle.
A 6-day environmental adaptation period was allowed prior to use
of these animals for experiments.
Tumors
For in vivo experiments, B16 melanoma cells were transplanted by
subcutaneous injection of 5]105 tumor cells in a volume of 0.05 ml
of Hank’s solution into the lower part of thigh, where hyperthermiarelated damage to intra-abdominal organs could be avoided. Tumors grew to diameters of 6—7 mm within 7—9 days after injection of
the cell suspension. All experiments were performed with this size of
tumor.
Treatment of B16 melanoma solid tumor in vivo
Ninety-six tumor-bearing mice were divided into 12 groups for
different treatments as shown in Table 1. Each group included eight
tumor-bearing mice. Body weight was measured daily, and evidence
3
Table 1. Treatment groups. Each mouse was given saline or
mitomycin C (MMC) and/or flavone acetic acid (FAA), with or
without hyperthermia
Group
30 min before to 4 h after administration of FAA in four tumorbearing mice.
Temperature
(°C)
Treatment
1
2
3
4
5
6
37.0
37.0
37.0
37.0
37.0
37.0
NaCl
MMC (2 mg/kg)
MMC (4 mg/kg)
FAA (150 mg/kg)
MMC (2 mg/kg)#FAA (150 mg/kg)
MMC (4 mg/kg)#FAA (150 mg/kg)
Statistical differences in data were analyzed by Student’s t-test,
where P values of less than 0.05 were considered to be significant.
7
8
9
10
11
12
43.0
43.0
43.0
43.0
43.0
43.0
NaCl
MMC (2 mg/kg)
MMC (4 mg/kg)
FAA (150 mg/kg)
MMC (2 mg/kg)#FAA (150 mg/kg)
MMC (4 mg/kg)#FAA (150 mg/kg)
Effect on colony formation
of gastrointestinal toxicity, as determined by the presence of bloody
diarrhea, was recorded at this time. In combination experiments,
drugs were administered just prior to HT, which was induced by
immersing the tumor-bearing lower part of the mouse thigh into
a circulating water bath (Model T-10, Thermonics, Tokyo, Japan) at
43°C for 15 min. Control mice were exposed to normothermic (37°C)
treatment for 15 min.
The mean tumor volume of each group at the time of treatment on
day 0 was similar. Control groups of mice received saline instead of
drugs. Tumor size was measured with a digital caliper (DP-1 HS,
Mitutoyo, Tokyo, Japan) every day after treatment. Body weight
and macroscopic evidence of gross gastrointestinal toxicity (such as
diarrhea or nasal and urogenital bleeding) were also recorded daily.
Tumor volume was determined from measurement of two perpendicular diameters by use of the following formula [5]:
Statistical analysis
Results
The cytotoxic effects of FAA and/or MMC (#/!HT)
in B16 melanoma cells are shown in Fig. 1. At the
normal body temperature of 37°C, MMC (1 lg/ml)
cytotoxicity was not enhanced by coincubation with
FAA up to concentrations of 100 lg/ml (Fig. 1A). Exposure of cells to HT (43°C, 60 min) produced a heatmediated increase in cytotoxicity of MMC (3.8-fold)
and FAA (1.8-fold) relative to drug responses obtained
at 37°C. The enhancement of MMC cytotoxicity by
heat, however, was independent of the relative FAA
concentration to which cells were exposed (Fig. 1B).
Tumor volume"1/2]length](width)2
Relative tumor volume, tumor growth time (TGT), and tumor
growth delay (TGD) were used to evaluate the antitumor effect.
Relative tumor volume was determined from the ratio of tumor
volume on each day of treatment to the initial tumor volume on day
0. TGT was calculated as the time required to reach twice the initial
tumor volume. TGD was calculated by subtracting the TGT of the
control tumor from that of treated tumors.
Timing and sequence of drugs and heat
The relative antitumor efficacy of FAA followed by MMC compared
to MMC followed by FAA was explored without exposure of mice
to hyperthermia. These studies consisted of FAA (150 mg/kg) being
administered at !4, !2, !1, 0, #1, #2, and #4 h relative to
administration of MMC (4 mg/kg; hour 0). Once the optimal sequence of compounds was found, the relative antitumor efficacy
produced by the sequence of drugs followed by HT (43°C, 15 min)
was examined.
Measurement of tumor blood flow
Tumor and muscle blood flow of mice, treated with FAA
(150 mg/kg) alone, were measured with a laser blood flowmeter and
flow probe (Biomedical Science, Kanazawa, Japan) [28]. After immobilization of the animal, a small incision was made in the skin and
tumor surface to introduce the probe, where it was then fixed at
a central location over the tumor or muscle tissue. The blood flow of
muscle, as control tissue, and of the tumor were measured from
Fig. 1 Survival fraction of B16 melanoma cells exposed to
mitomycin C (MMC) and flavone acetic acid (FAA) at 37°C (A) or
43°C (B) for 60 min. The concentrations of MMC were: 0 lg/ml (d),
0.1 lg/ml (s), 1 lg/ml (h), 5 lg/ml (n). Data are presented as
mean$SD from three experiments
4
of cells after exposure to MMC was only slightly decreased at a pH less than 7.0, with a survival fraction of
7.7]10~1 at pH 7.4 and 6.9]10~1 at pH 6.5. Under
hypoxic conditions, the cytotoxicity of MMC in combination with HT was significantly enhanced, especially
at an acidic pH. The survival fraction of cells was
7.5]10~2 at pH 7.4 and 3.8]10~2 at pH 6.5. The
cytotoxicity of MMC was most enhanced in combination with HT at an acidic pH under hypoxic
conditions.
Effect on B16 melanoma solid tumors
Fig. 2 Survival fraction of hypoxic B16 melanoma cells exposed to
MMC (1 lg/ml) at various pHs with or without hypoxia and hyperthermia. Hypoxic cells were preincubated for 3 h and exposed to
MMC for 1 h under hypoxic conditions. Symbols: MMC under
aerobic conditions at 37°C (d), MMC under aerobic conditions at
43°C (s), MMC under hypoxic conditions at 37°C (j), MMC under
hypoxic conditions at 43°C (h). Data are presented as mean$SD
from three experiments
The survival of B16 melanoma cells exposed to
MMC (1 lg/ml) at various pHs with or without HT
under aerobic and hypoxic condition is presented in
Fig. 2. Under aerobic conditions, the survival fraction
Fig. 3 Growth curves of B16
melanoma tumors in
C57BL/6NCrj male mice treated
with various combinations of
MMC and/or FAA under
normothermic (A) or
hyperthermic (B) conditions.
Relative tumor volume was
expressed as the ratio of tumor
volume on each day to initial
tumor volume at time of
treatment. Symbols: Control (d),
2 mg/kg MMC (m), 4 mg/kg
MMC (j), 150 mg/kg FAA (s),
2 mg/kg MMC#150 mg/kg
FAA (n), 4 mg/kg
MMC#150 mg/kg FAA (h).
Data are presented as
mean$SD of tumor
measurements from eight mice.
Arrow indicates first day of drug
treatment
Tumor growth curves after treatment with FAA
(150 mg/kg) alone or in combination with MMC
(2 mg/kg or 4 mg/kg) with or without HT (43°C,
15 min) are shown in Fig. 3. FAA or HT alone showed
minimal effects on tumor growth. Treatment with FAA
(150 mg/kg) plus MMC (4 mg/kg) in combination with
HT, however, resulted in a significant reduction in
tumor volume. TGT data for FAA and/or MMC with
or without HT are summarized in Table 2. TGT in the
control group was 4.3$1.0 days. TGT for MMC
(2 mg/kg) alone, FAA (150 mg/kg) alone, and MMC
plus FAA was 5.8$1.3, 5.2$1.2, and 6.2$1.1 days,
respectively. There were no significant differences in
TGT compared to that of control groups. In combination with HT, however, the antitumor effects of FAA,
MMC (4 mg/kg), FAA plus MMC (2 mg/kg), and FAA
plus MMC (4 mg/kg) were all significantly enhanced
(P(0.05) compared to respective groups without HT.
5
Table 2. Tumor growth time (¹G¹), tumor growth delay (¹GD),
and body weight changes after treatment with FAA, MMC and
hyperthermia, either alone or in combination. Data are presented as
mean$SD
Group!
TGT (days)"
TGD (days)#
Body weight change (%)$
1
2
3
4
5
6
4.3$1.0
5.8$1.3
6.8$0.9
5.2$1.2
6.2$1.1
8.5$0.7
0.0
1.5
2.5
0.9
1.9
4.2
99.8
100.9
98.9
98.8
97.9
99.1
7
8
9
10
11
12
5.2$1.2
6.6$1.1
9.0$1.1%
7.6$0.5%
10.3$1.1%
15.0$1.8%
0.9
2.3
4.7
3.3
6.0
10.7&
99.4
97.8
98.4
97.1
98.8
97.9
! See Table 1 for explanations of the treatment groups
" TGT was calculated as time required to reach a tumor volume
twice that of the initial tumor volume
# TGD was calculated by subtracting the tumor growth time of the
control group from that of treated group
$ The mean body weights on day 7, expressed as percentage of that
on day 0 in each group
% Significantly different from the same dose without hyperthermia
(P(0.05)
& Significantly different from all other groups (P(0.01)
The greatest enhancement of antitumor effect of
MMC (4 mg/kg) was observed when it was combined
with FAA and HT. This response was larger than the
sum of the two treatments given separately. Mean body
weight 7 days after treatment in all treated groups
revealed no significant difference from the control
group. The mice tolerated these doses of FAA plus
MMC with HT well and there was no obvious toxicity
or deaths.
As shown in Fig. 4A, the antitumor effect of MMC
was substantially increased when FAA was administered after rather than before administration of MMC.
When combined with HT, the maximum antitumor
effect was observed when FAA was administered 1 h
after MMC (Fig. 4B).
Fig. 4A Effect of scheduling of MMC and FAA without hyperthermia (H¹) on mouse tumor volume. Data are presented as
mean$SD of relative tumor volumes in mice (n"6) treated with
MMC (4 mg/kg) and/or FAA (150 mg/kg) at various times.
Measurements of relative tumor volumes were made on day 10 in
each group. FAA was administered at !4, !2, !1, 0, #1, #2,
and #4 h relative to administration of MMC at time 0. B Effect of
scheduling of MMC (4 mg/kg), FAA (150 mg/kg), and HT (43°C,
15 min) on mouse tumor volume. Data are presented as the relative
tumor volumes on day 10 in each group. HT was added 2 h after
administration of the final drug (see above). Asterisk indicates,
significant difference (P(0.05) between administration of FAA 1 h
after compared to 1 h before MMC treatment
Discussion
Blood flow
Figure 5 shows the effect of FAA (150 mg/kg) on both
intra-tumoral and intra-muscular blood flow. The
mean initial blood flow in the tumor was 88% of that in
the muscle. Although the blood flow in the muscle
remained unchanged after administration of FAA, tumor blood flow was significantly reduced to approximately 25% of initial muscle blood flow within 10 min
after injection of FAA, and remained at this low
flow rate for about 2 h before gradually returning to
normal.
We have shown that the cytotoxicity of MMC is enhanced in vitro when cells are exposed to hypoxic
conditions. The most marked enhancement was observed at an acidic pH in combination with HT. This is
in agreement with other in vitro studies of oxygen
dependence of cell killing by MMC [20]. MMC requires reductive transformation of its quinone group by
either DT-diaphorase [8, 25] or NADPH cytochrome
c reductase [15, 19] in order to exhibit alkylating
activity. Under hypoxic conditions, certain enzyme
systems are capable of transforming MMC to active
metabolites [16, 17] through addition of electrons.
6
Fig. 5 Changes in blood flow of s.c. B16 melanoma tumor and
muscle in mice treated with FAA (150 mg/kg). Blood flow was
measured with a laser blood flowmeter. Symbols: muscle blood flow
(s), tumor blood flow (d). Data are presented as mean$SD from
four experiments. Asterisk indicates significant difference (P(0.05)
for four treatment groups whose blood flow was altered by administration of FAA relative to their respective control values. Arrow
indicates time of FAA administration
This phenomenon results in enhanced cytotoxicity of
MMC toward hypoxic subpopulations within solid tumors [16] by producing interstrand DNA cross-links
[23]. Under acidic conditions, the cell-killing effect of
heat is also enhanced [42] because of the combined
effect of acidosis-induced lysosomal activity and heatinduced cell membrane damage [31, 32].
Our results clearly demonstrate that the cytotoxicity
of MMC was enhanced by FAA in combination with
HT in vivo, but not in vitro. In vitro, this result is
explained by the fact that the mechanism of FAA is
mainly based on a host-mediated action, such as reduction of tumor blood flow [45] and enhancement of the
immune system [3, 10]. In vivo, significant differences
were noted between the treatment of FAA given 1 h
before as opposed to 1 h following MMC administration. As MMC has reached its maximum plasma concentration within almost 1 h in tumor-bearing male
DBA/2J mice after i.p. administration of MMC [6], it
seems possible that the maximal plasma concentration
of MMC, given i.p. in C57/BL mice, also occurs within
this time. Reduction of tumor blood flow occurs within
10 min after FAA administration. Thus, with the administration of MMC 1 h preceding FAA, peak plasma
levels of MMC in mice would occur before the FAAmediated reduction in tumor blood flow. This may
result in MMC being trapped and maintained within
the tumor at a high concentration. The reduced tumor
blood flow with resulting hypoxia would tend to optimize the metabolism of MMC to active cytotoxic species and enhance cell killing effectiveness. When combined with HT, the increase in antitumor efficacy of the
combined treatment may be explained by the fact that
the FAA-mediated hypoxic condition has been shown
to increase antitumor activity of HT alone as well as
that of MMC alone [16, 37]. The combined effect of
MMC plus HT was also obserevd in the in vitro hypoxic experimental model. When FAA was administered before MMC, FAA-induced lower tumor blood flow
may have restricted the uptake of MMC into the tumors. Even when combined with HT, enhancement of
the combined antitumor effect was limited. Thus, the
increase in antitumor effect of MMC on B16 melanoma
seems to be critically dependent on the time of its
administration relative to that of FAA.
Duke et al. [7] reported the i.p. administration of
FAA (200 mg/kg) produced a 60% reduction in MAC
26 tumor blood volume using an Evan’s blue perfusion
technique, which was first demonstrated 4 h after treatment and persisted for 24 h. Zwi et al. [45] reported
that perfusion of colon 38 tumors, using the fluorescent
stain, H33342, was reduced to 50% of controls within
3 h of i.p. administration of FAA (1.2 mmol/kg) and
was completely inhibited by 24 h. Several factors such
as tumor type, animal species, route of administration
of FAA, and method of measurement of blood flow
may influence the actual extent of reduction in tumor
blood flow. There are now several proposed mechanisms of FAA-induced reduction of tumor blood flow.
These include a change in endothelial barrier function
leading to increased vascular permeability [43], an
alteration of platelet function through inhibition of
platelet adhesion [36], an increase in intravascular
coagulopathy [26], and vascular failure mediated by
induction of tumor necrosis factor [24].
There have been several reports that vasoactive
drugs, which can selectively reduce the blood flow of
tumors but not that of normal tissues, enhance the
antitumor effect of hypoxic-target antitumor drugs and
bioreductive drugs. Reduction of tumor blood flow
could be potentially useful for enhancing the antitumor
effect of such antitumor drugs and HT [11, 39]. In the
present study, we have shown that, in a solid tumor,
cytotoxicity of MMC was significantly enhanced by
administration of FAA in combination with HT, and
that marked enhancement was achieved when FAA
was given 1 h after MMC, followed by HT. Although
FAA alone has failed to show antitumor effects in
clinical trials at present, it is currently being investigated for a potential synergistic effect with interleukin
2. FAA may be effective in inducing hypoxic conditions
in human solid tumors, which may lead to enhancement of the amtitumor effect of hypoxic-target agents
such as MMC. The enhanced antitumor efficacy of the
combined treatment may represent a novel approach to
selective therapy of human solid tumors, which includes hypoxic subpopulations. However, before clinical application of our proposed chemo-hyperthermia
treatment, a detailed evaluation of the desired effect of
FAA on human tumors, followed by combination with
a single and then a multiple treatment therapy must be
carried out in preclinical experiments. Pharmacokinetic
7
determination of MMC and FAA within tumors and
the determination of these concentrations within the
peripheral circulation may help in an understanding of
the efficacy of this novel combination of treatments.
References
1. Begg AC, Shrieve DC, Smith KA, Terry NH (1985) Effects of
hypoxia, pH, and growth stage on cell killing in Chinese hamster
V79 cells in vitro by activated cyclophosphamide. Cancer Res
45 : 3454
2. Bibby MC, Double JA, Phillips RM, Loadman PM (1987)
Factors involved in the anti-cancer activity of the investigational agents LM985 (flavone acetic acid ester) and LM975
(flavone acetic acid). Br J Cancer 55 : 159
3. Bibby MC, Double JA, Loadman PM (1988) Unique chemosensitivity of MAC 16 tumours to flavone acetic acid (LM975, NSC
347512). Br J Cancer 58 : 341
4. Bull JM, Chretien PB (1976) Editorial: Heat as cancer therapy,
J Am Med Assoc 235 : 2223
5. Carlsson G, Gullberg B, Hafstrom L (1983) Estimation of liver
tumor volume using different formulas: an experimental study in
rats. J Cancer Res Clin Oncol 105 : 20
6. Dorr RT, Alberts DS, Liddil JD (1988) Mitomycin C toxicity
and pharmacokinetics in mice given sulfur nucleophiles. Anticancer Res 8 : 733
7. Duke CV, Double JA, Bibby MC (1988) Flavone acetic acid
(LM975, NSC 347512) induces rapid massive necrosis in
a murine transplantable adenocarcinoma (MAC 26). Br J Cancer 58 : 532
8. Dulhanty AM, Li M, Whitmore GF (1989) Isolation of Chinese
hamster ovary cell mutants deficient in excision repair and
mitomycin C bioactivation. Cancer Res 49 : 117
9. Evelhoch JL, Bissery MC, Chabot GG, Simpson NE, McCoy
CL, Heilbrun LK, Corbett TH (1988) Flavone acetic acid (NSC
347512) induced modulation of murine tumor physiology
monitored by in vivo nuclear magnetic response spectroscopy.
Cancer Res 48 : 4749
10. Finlay GJ, Smith GP, Fray LM, Baguley BC (1988) Effect of
flavone acetic acid on Lewis lung carcinoma; evidence for an
indirect effect. J Natl Cancer Inst 80 : 241
11. Fujimoto S, Kobayashi K, Takahashi M, Konno C, Kokubun
M, Ohta M, Shrestha RD, Kiuchi S (1992) Effects on tumour
microcirculation in mice of misonidazole and tumour necrosis
factor plus hyperthermia. Br J Cancer 65 : 33
12. Gerweck LE (1977) Modification of cell lethality at elevated
temperatures. The pH effect. Radiat Res 70 : 224
13. Herman TS, Teicher BS, Jochelson M, Clark J, Svensson G,
Coleman CN (1988) Rationale for use of local hyperthermia
with radiation therapy and selected anticancer drugs in locally
advanced human malignancies. Int J Hyperthermia 4 : 143
14. Hiraoka M, Jo S, Dodo Y, Ono K, Takahashi M, Nishida H,
Abe M (1984) Clinical results of radiofrequency hyperthermia
combined with radiation in the treatment of radioresistant cancers. Cancer 54 : 2898
15. Hoban PR, Walton MI, Robson CN, Godden J, Stratford IJ,
Workman P, Harris AL, Hickson ID (1990) Decreased
NADPH: cytochrome P-450 reductase activity and impaired
drug activation in a mammalian cell line resistant to mitomycin
C under aerobic but not hypoxic conditions. Cancer Res
50 : 4692
16. Kennedy KA, Rockwell S, Sartorelli AC (1980) Preferential
activation of mitomycin C to cytotoxic metabolites by hypoxic
tumor cells. Cancer Res 40 : 2356
17. Kennedy KA, Sligar SG, Polomski L, Sartorelli AC (1982)
Metabolic activation of mitomycin C by liver microsomes and
nuclei. Biochem Pharmacol 31 : 2011
18. Kerr DJ, Maughan T, Newlands E, Rustin G, Bleehen NM,
Lewis C, Kaye SB (1989) Phase II trial of flavone acetic acid in
advanced malignant melanoma and colorectal carcinoma. Br
J Cancer 60 : 104
19. Keyes SR, Fracasso PM, Heimbrook DC, Rockwell S, Sligar
SG, Sartorelli AC (1984) Role of NADPH: cytochrome c reductase and DT-diaphorase in the biotransformation of mitomycin
C. Cancer Res 44 : 5638
20. Kohnoe S, Emi Y, Takahashi I, Yoshida M, Maehara Y,
Sugimachi K (1991) Hypoxia and acidity increase the cytotoxicity of mitomycin C and carboquone to human tumor cells in
vitro. Anticancer Res 11 : 1401
21. Kusumoto T, Maehara Y, Sakaguchi Y, Saku M, Sugimachi
K (1989) Hypoxia enhances the lethality of mitomycin C and
carboquone against human malignant tumor cells in vitro. Eur
Surg Res 21 : 224
22. Kusumoto T, Maehara Y, Sakaguchi Y, Kohnoe S, Emi Y,
Sugimachi K (1991) Sarcoma-180 cells and human colorectal
tumor cells under in vitro hypoxic conditions are more sensitive
to mitomycin C and carboquone. Eur J Surg Oncol 17 : 358
23. Lown JW (1979) The molecular mechanism of antitumor action
of the mitomycin C. Current status and new development.
Academic Press, New York, p 5
24. Mahadevan V, Malik STA, Meager A, Fiers W, Lewis GP, Hart
IR (1990) Role of tumor necrosis factor in flavone acetic acid
induced tumor vascular shutdown. Cancer Res 50 : 5537
25. Marshall RS, Paterson MC, Rauth AM (1989) Deficient activation by a human cell strain leads to mitomycin C resistance
under aerobic but not hypoxic conditions. Br J Cancer 59 : 341
26. Murray JC, Smith KA, Thurston G (1989) Flavone acetic acid
induces a coagulopathy in mice. Br J Cancer 60 : 729
27. Murray JC, Smith KA, Stern DM (1991) Flavone acetic acid
potentiates the induction of endothelial procoagulant activity
by tumor necrosis factor. Eur J Cancer 27 : 765
28. Nakai M, Tamaki K, Ogata J, Matsui Y, Maeda M (1993)
Parasympathetic cerebrovasodilator center of the facial nerve.
Circ Res 72 : 470
29. Nielsen OS, Overgaard J (1977) Effect of extracellular pH on
thermotolerance and recovery of hyperthermic damage in vitro.
Cancer Res 39 : 2772
30. Olver IN, Webster LK, Bishop JF, Stokes KH (1992) A phase
I and pharmacokinetic study of 12-h infusion of flavone acetic
acid. Cancer Chemother Pharmacol 29 : 354
31. Overgaard J (1976) Influence of extracellular pH on the viability
and morphology of tumor cells exposed to hyperthermia. J Natl
Cancer Inst 56 : 1243
32. Overgaard J, Bichel P (1977) The influence of hypoxia and
acidity on the hyperthermia response of malignant cells in vitro.
Radiology 123 : 511
33. Plowman J, Narayanan VL, Dykes D, Szarvasi E, Briet P,
Yoder OC, Paull KD (1986) Flavone acetic acid: a novel agent
with preclinical antitumor activity against colon adenocarcinoma 38 in mice. Cancer Treat Rep 70 : 631
34. Power JA, Harris JW (1977) Response of extremely hypoxic
cells to hyperthermia: survival and oxygen enhancement ratios.
Radiology 123 : 767
35. Rockwell S, Kennedy KA (1979) Combination therapy with radiation and mitomycin C: preliminary results with EMT6 tumor
cells in vitro and in vivo. Int J Radiat Oncol Biol Phys 5 : 1673
36. Rubin J, Ames MM, Schutt AJ, Nichols WL, Bowie EJW,
Kovach JS (1987) Flavone-8-acetic acid inhibits ristocetininduced platelet agglutination and prolongs bleeding time.
Lancet 7 : 1081
37. Sakaguchi Y, Maehara Y, Baba H, Kusumoto T, Sugimachi K,
Newman RA (1992) Flavone acetic acid increases the antitumor
effect of hyperthermia in mice. Cancer Res 52 : 3306
38. Smith GP, Calveley SB, Smith MJ, Baguley BC (1987) Flavone
acetic acid (NSC 347512) induces haemorrhagic necrosis of
mouse colon 26 and 38 tumours. Eur J Cancer Clin Oncol
23 : 1209
8
39. Stratford IJ, Adams GE, Godden J, Nolan J, Timpson NHN
(1988) Potentiation of the anti-tumour effect of melphalan by
the vasoactive agent, hydralazine. Br J Cancer 58 : 122
40. Sugimachi K, Matsuda H, Ohno S, Fukuda A, Matsuoka H,
Mori M, Kuwano H (1988) Long term effects of hyperthermia
combined with chemotherapy and irradiation for the treatment
of patients with carcinoma of the esophagus. Surg. Gynecol
Obstet 167 : 319
41. Teicher BA, Lazo JS, Sartorelli AC (1981) Classification of
antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res 41 : 73
42. Vaupel P, Kallinowski F, Okunieff P (1989) Blood flow, oxygen
.
and nutrient supply, and metabolic microenvironment of human
tumors: a review. Cancer Res 49 : 6449
43. Watts ME, Woodcock M (1922) Flavone acetic acid induced
changes in human endothelial permeability: potentiation by
tumor-conditioned medium. Eur J Cancer 28 : 1628
44. Wiltrout RH, Boyd MR, Back TC, Salup RR, Arthur JA, Hornung RL (1988) Flavone-8-acetic acid augments systemic natural killer cell activity and synergizes with IL-2 for treatment of
murine renal cancer. J Immunol 140 : 3261
45. Zwi LJ, Baguley BC, Gavin JB, Wilson WR (1990) The use of
vascularised spheroids to investigate the action of flavone acetic
acid on tumour blood vessels. Br J Cancer 62 : 231
.